GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
NEW YORK, March 17, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of purchasers of NantHealth, Inc. securities (NASDAQ:NH) (“NantHealth” or the “Company”): (1) pursuant or traceable to NantHealth’s initial public offering on or about June 1, 2016; and/or (2) from June 1, 2016 through March 6, 2017, inclusive (the “Class Period”).
Investors who have incurred losses in the shares of NantHealth, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have purchased shares of NantHealth, Inc and would like to assist with the litigation process, you may, no later than May 8, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that: (1) NantHealth founder Patrick Soon-Shiong donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) as such, Nanthealth and Soon-Shiong violated federal tax laws—exposing Nanthealth to possible civil and criminal liability; (3) Nanthealth improperly recorded orders received from the University of Utah as GPS Cancer test orders; (4) in turn, Nanthealth reported false and inflated GPS Cancer order figures for the third quarter of 2016; and (5) as a result, defendants’ statements regarding NantHealth’s outlook and expected financial performance were false and misleading and lack a reasonable basis when made.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
Follow the firm and learn about newly filed cases on Twitter and Facebook.
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
